Provectus Biopharmaceuticals Stock Current Valuation
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Valuation analysis of Provectus Biopharmaceutica helps investors to measure Provectus Biopharmaceutica's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Provectus Biopharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Provectus Biopharmaceutica is based on 3 months time horizon. Increasing Provectus Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Provectus Biopharmaceuticals is useful when determining the fair value of the Provectus otc stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Provectus Biopharmaceutica. Since Provectus Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Provectus OTC Stock. However, Provectus Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.11 | Real 0.0946 | Hype 0.11 |
The real value of Provectus OTC Stock, also known as its intrinsic value, is the underlying worth of Provectus Biopharmaceutica OTC Stock, which is reflected in its stock price. It is based on Provectus Biopharmaceutica's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Provectus Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Provectus Biopharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Provectus Biopharmaceuticals helps investors to forecast how Provectus otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Provectus Biopharmaceutica more accurately as focusing exclusively on Provectus Biopharmaceutica's fundamentals will not take into account other important factors: Provectus Biopharmaceuticals OTC Stock Current Valuation Analysis
Provectus Biopharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Provectus Biopharmaceutica Current Valuation | 46.73 M |
Most of Provectus Biopharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provectus Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Provectus Biopharmaceuticals has a Current Valuation of 46.73 M. This is 99.67% lower than that of the Pharmaceuticals sector and 98.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.72% higher than that of the company.
Provectus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in current valuation category among related companies.
Provectus Fundamentals
| Return On Asset | -1.85 | ||||
| Operating Margin | (4.77) % | ||||
| Current Valuation | 46.73 M | ||||
| Shares Outstanding | 419.55 M | ||||
| Shares Owned By Insiders | 3.69 % | ||||
| Shares Owned By Institutions | 0.04 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 5.44 X | ||||
| Price To Sales | 55.94 X | ||||
| EBITDA | (4.56 M) | ||||
| Net Income | (5.54 M) | ||||
| Cash And Equivalents | 84.27 K | ||||
| Total Debt | 2.29 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 0.27 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (1.01 M) | ||||
| Short Ratio | 0.47 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 3.5 | ||||
| Beta | 0.5 | ||||
| Market Capitalization | 44.47 M | ||||
| Total Asset | 3.51 M | ||||
| Retained Earnings | (180.8 M) | ||||
| Working Capital | 10.6 M | ||||
| Current Asset | 14.72 M | ||||
| Current Liabilities | 4.12 M | ||||
| Z Score | -59.7 | ||||
| Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Provectus Biopharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Provectus Biopharmaceutica's short interest history, or implied volatility extrapolated from Provectus Biopharmaceutica options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Provectus Biopharmaceutica using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |